Current therapies for NOMID and related disorders primarily involve biologics against IL1R1 signaling such as Anakinra (a recombinant IL1R antagonist), Canakinumab (an antibody targeting Il-1β), and Rilonacept (a soluble decoy receptor). The gene discussed is IL1R1; the disease is CINCA syndrome.